Avanos Medical Inc (AVNS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Avanos Medical Inc stock (AVNS) is currently trading at $13.65. Avanos Medical Inc PS ratio (Price-to-Sales) is 0.87. Analyst consensus price target for AVNS is $14.00. WallStSmart rates AVNS as Sell.
- AVNS PE ratio analysis and historical PE chart
- AVNS PS ratio (Price-to-Sales) history and trend
- AVNS intrinsic value — DCF, Graham Number, EPV models
- AVNS stock price prediction 2025 2026 2027 2028 2029 2030
- AVNS fair value vs current price
- AVNS insider transactions and insider buying
- Is AVNS undervalued or overvalued?
- Avanos Medical Inc financial analysis — revenue, earnings, cash flow
- AVNS Piotroski F-Score and Altman Z-Score
- AVNS analyst price target and Smart Rating
Avanos Medical Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Avanos Medical Inc (AVNS) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Avanos Medical Inc (AVNS) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
99.43% of shares held by major funds and institutions
Supporting Valuation Data
Avanos Medical Inc (AVNS) Areas to Watch (6)
Company is destroying shareholder value
Earnings declining -37.50%, profits shrinking
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Revenue growing slowly at 0.70% annually
Small-cap company with higher risk but more growth potential
Avanos Medical Inc (AVNS) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 3 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, Institutional Own.. Valuation metrics including Price/Sales (0.87), Price/Book (0.78) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Growth concerns include Revenue Growth at 0.70%, EPS Growth at -37.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -9.08%, Operating Margin at 1.99%, Profit Margin at -10.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -9.08% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 0.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AVNS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AVNS's Price-to-Sales ratio of 0.87x sits near its historical average of 0.9x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 10% below its historical high of 0.96x set in Feb 2026, and 0% above its historical low of 0.87x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Avanos Medical Inc (AVNS) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Avanos Medical Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 701M with 1% growth year-over-year. The company is currently unprofitable, posting a -10.4% profit margin.
Key Findings
Generating 21M in free cash flow and 28M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -10.4% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Avanos Medical Inc.
Bottom Line
Avanos Medical Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Avanos Medical Inc(AVNS)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Avanos Medical, Inc. is a medical technology company focused on providing medical device solutions to improve the quality of life for patients in North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America. The company is headquartered in Alpharetta, Georgia.